NASDAQ: XERSXeris Biopharma Holdings Inc Stock
$5.61+0.17 (+3.13%)
Updated Mar 23, 2026
XERS Priceļ»æ
$5.61
Fair Value Price
N/A
Market Capļ»æ
$967.34M
52 Week Lowļ»æ
$3.81
52 Week Highļ»æ
$10.08
P/Eļ»æ
N/A
P/Bļ»æ
70.67x
P/Sļ»æ
4.32x
PEGļ»æ
N/A
Dividend Yieldļ»æ
N/A
Revenueļ»æ
$291.85M
Earningsļ»æ
$554.00k
Gross Marginļ»æ
85.4%
Operating Marginļ»æ
10.16%
Profit Marginļ»æ
0.2%
Debt to Equityļ»æ
27.02
Operating Cash Flow
$29M
Betaļ»æ
1.23
Next Earningsļ»æ
May 7, 2026
Ex-Dividendļ»æ
N/A
Next Dividendļ»æ
N/A
XERS Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XERS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XERS
Ranked#13 of 469
Ranked#13 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.54 | A | |
| $16.01 | A | |
| $182.32 | A |
Be the first to know about important XERS news, forecast changes, insider trades & much more!
XERS News
Overview
Due Diligence Score
ā
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XERS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XERS is poor value based on its book value relative to its share price (70.67x), compared to the US Biotechnology industry average (4.63x)
P/B vs Industryļ»æ Valuation
XERS's Earnings (EBIT) of $29.64M are insufficient to safely cover interest payments on company debt ($258.10M)
Interest Coverageļ»æ Financials
XERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growthļ»æ Financials
There are 30 more XERS due diligence checks available for Premium users.
Valuation
XERS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
26.93x
Market
31.38x
XERS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
70.67x
Industry
4.63x
XERS is poor value based... subscribe to Premium to read more.
P/B vs Industryļ»æ Valuation
XERS's financial health
Profit margin
Revenue
$85.8M
Net Income
$11.1M
Profit Margin
12.9%
XERS's Earnings (EBIT) of $29.64M... subscribe to Premium to read more.
Interest Coverageļ»æ Financials
XERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growthļ»æ Financials
Assets to liabilities
Assets
$383.5M
Liabilities
$369.8M
Debt to equity
27.02
XERS's short-term assets ($240.31M) exceed... subscribe to Premium to read more.
Short-term Liabilitiesļ»æ Financials
XERS's long-term liabilities ($260.26M) exceed... subscribe to Premium to read more.
Long-term Liabilitiesļ»æ Financials
XERS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debtļ»æ Financials
XERS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equityļ»æ Financials
Cash flow
Operating
$20.0M
Investing
-$333.0k
Financing
-$266.0k
XERS's operating cash flow ($28.63M)... subscribe to Premium to read more.
Debt Coverageļ»æ Financials
XERS vs Biotech Stocks
Xeris Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.